Alemtuzumab induced hemodynamic change in relapsing multiple sclerosis occurs independent of corticosteroid premedication – a retrospective multicentre study

Acute infusion effects in relapsing multiple sclerosis patients receiving alemtuzumab under a modified prophylaxis regimen

“…This timing suggests that these VS changes reflect acute increases in cytokine levels following opsonization of CD52 cells by alemtuzumab. The same Day 1-specific pattern of HR and/or temperature increase has been reported previously (Thomas et al, 2016;Chinea et al, 2020;Di Pauli et al, 2022), indicating that it is not specific to the modified peri-infusion regimen.…”

Alemtuzumab infusion-associated reactions and laboratory changes in patients with relapsing-remitting multiple sclerosis at baseline and first-year follow-up

“…To record a review of etiology after case series of disseminated cerebral hemorrhages with ATZ infusion. This was previously thought to be caused by an increase in mean daily blood pressure (SBP range from 15% to 55% with a peak range of up to 68%) [ 3 ]. A hypertensive hemorrhagic stroke resulting in death after infusion has been reported in the European Medicines Agency database.…”

“…A hypertensive hemorrhagic stroke resulting in death after infusion has been reported in the European Medicines Agency database. In addition to studies indicating increases in SBP and DBP during infusion, there are also studies in which only an increase in SBP or no change was observed [ [1] , [3] , [5] , [6] ]. Different results may be related to patient selection, various risk factors (age, body mass index, smoking, cardiovascular disorders, etc.…”

“…Changes in vital parameters can be seen after the infusion. Only results in systolic blood pressure, increase in systolic and diastolic blood pressure, or no change were reported [ [3] , [4] , [5] , [6] ]. There may also be a slight but insignificant increase in heart rate [ 7 ].…”

Alemtuzumab treatment for multiple sclerosis in Austria: An observational long‐term outcome study

“…While the majority of patients who developed acute coronary syndrome had cerebrovascular risk factors, no particular pattern of risk factors was identified among patients with cerebral stroke 44,45 . In this regard, ALEM administration is associated with increased blood pressure, and vital signs should be closely monitored before and during infusion 44–46 . These postmarketing safety issues led to EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommendation in 2019 that ALEM must no longer be used in patients with certain heart, circulation or bleeding disorders, or in patients who have autoimmune disorders other than MS 47,48 .…”